BioXcel Corporation
BioXcel LLC is an AI-enabled drug discovery and development company that applies machine learning, natural language processing and biomedical data integration to accelerate target discovery, asset prioritization, repurposing and clinical development. The organization offers services to biopharma partners and operates a proprietary AI platform used to analyze literature, clinical and real-world data to support R&D decision making. The company has supported programs that proceeded to regulatory approval and maintains a family of affiliated companies focused on AI-driven drug discovery and therapeutics.
Industries
Nr. of Employees
small (1-50)
BioXcel Corporation
Products
Proprietary AI platform for drug discovery
A multi-modal artificial intelligence platform that integrates literature, clinical trials, genomic and intervention data to generate hypotheses, knowledge graphs and predictive models for discovery and development.
Proprietary AI platform for drug discovery
A multi-modal artificial intelligence platform that integrates literature, clinical trials, genomic and intervention data to generate hypotheses, knowledge graphs and predictive models for discovery and development.
Services
AI-powered drug discovery and development
End-to-end AI-enabled discovery and development services combining human scientific expertise with proprietary machine-learning models to accelerate target-to-clinic programs.
Early innovation & discovery support
Target identification, pathway analysis and biomarker discovery using integrated literature and omics data to build a preclinical foundation.
Pipeline analysis & optimization
Portfolio-level analyses including competitive landscape, trial benchmarking, TPP development, market sizing and NPV/sales forecasting to inform prioritization.
Licensing & deal support
Technical due diligence, asset benchmarking, value proposition development and deal strategy support for licensing transactions.
Re-Innovation and lifecycle management
Indication expansion, drug repositioning and regulatory pathway support (including 505(b)(2) strategies) to extend asset value.
AI-driven discovery partnerships
Flexible collaboration models including fully managed discovery programs, joint development and target scouting powered by AI.
AI-powered drug discovery and development
End-to-end AI-enabled discovery and development services combining human scientific expertise with proprietary machine-learning models to accelerate target-to-clinic programs.
Early innovation & discovery support
Target identification, pathway analysis and biomarker discovery using integrated literature and omics data to build a preclinical foundation.
Pipeline analysis & optimization
Portfolio-level analyses including competitive landscape, trial benchmarking, TPP development, market sizing and NPV/sales forecasting to inform prioritization.
Licensing & deal support
Technical due diligence, asset benchmarking, value proposition development and deal strategy support for licensing transactions.
Re-Innovation and lifecycle management
Indication expansion, drug repositioning and regulatory pathway support (including 505(b)(2) strategies) to extend asset value.
AI-driven discovery partnerships
Flexible collaboration models including fully managed discovery programs, joint development and target scouting powered by AI.
Expertise Areas
- AI-driven drug discovery
- Target identification and validation
- Drug repurposing and indication expansion
- Clinical development optimization and patient stratification
Key Technologies
- Machine learning and proprietary AI models
- Natural language processing (NLP)
- Knowledge graphs
- Multi-modal data integration (genomic, clinical, literature)